ENCANTO holds 3rd General Assembly in Dubrovnik to prepare phase II clinical trial
The ENCANTO project held its 3rd General Assembly on May 7–8, 2025, at Dubrovnik, Croatia. The two-day meeting brought together clinical partners, researchers, and coordinators from across Europe to align on key objectives ahead of the phase II clinical trial of ENCANTO’s groundbreaking nasal cartilage therapy for knee osteoarthritis.
The agenda focused on final preparations for trial site activation, regulatory updates, training on the revised clinical protocol, and manufacturing logistics. Presentations and discussions covered clinical trial readiness, physiotherapy integration, MRI protocol updates, biomarker collection, and quality control procedures.
The meeting concluded with a Steering Committee session and ENCANTO’s participation in the SEEFORT Conference, reinforcing the project’s commitment to scientific dialogue and cross-border cooperation in regenerative medicine.
